On 24 JUNE Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) said it sailed through one of the most crucial tests in its 25-year existence when its cystic fibrosis (CF) treatment hit goals in a late-stage study. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) net profit margin is -36.90% and weekly performance is 38.08%. On last trading day company shares ended up $89.86. Analysts mean target price for the company is $90.45. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) distance from 50-day simple moving average (SMA50) is 30.74%.
Prothena Corporation PLC (NASDAQ:PRTA) said it has priced an underwritten public offering of 4.75 million of its ordinary shares at $22.50 per ordinary share, before underwriting discounts and commissions. All the ordinary shares in the offering are to be sold by Prothena. Further, the underwriters were granted a 30-day option to buy up to an additional 712,500 ordinary shares. Prothena Corporation PLC (NASDAQ:PRTA) shares fell -5.28% in last trading session and ended the day on $21.89. PRTA return on assets is -9.30%. Prothena Corporation PLC (NASDAQ:PRTA) quarterly performance is -45.37%.
On 24 JUNE Actinium Pharmaceuticals Inc (NYSEMKT: ATNM) announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares are being offered by Actinium. Actinium Pharmaceuticals Inc (NYSEMKT: ATNM) shares moved down -18.97% in last trading session and was closed at $7.09, while trading in range of $6.93 – $7.50. Actinium Pharmaceuticals Inc (NYSEMKT: ATNM) year to date (YTD) performance is 20.37%.
On 19 JUNE Can Fite Biopharma Ltd (ADR) (NYSEMKT: CANF) announced the Company will exhibit at the Bio International Convention in San Diego on June 23(rd) through 26(th) , 2014 at the Israel Office of the Chief Scientist’s booth #611. The Company’s CEO, Dr. Pnina Fishman and its Director of Business Development, Dr. Sari Fishman will conduct one-on-one meetings with potential partners, as well as present findings from Can-Fite’s clinical programs to scientists and medical doctors attending the convention. Can Fite Biopharma Ltd (ADR) (NYSEMKT: CANF) ended the last trading day at $3.72. Company weekly volatility is calculated as 6.87%. Can Fite Biopharma Ltd (ADR) (NYSEMKT: CANF) showed a negative weekly performance of -2.87%.
On 24 JUNE OHR Pharmaceutical Inc (NASDAQ:OHRP) announced positive top-line interim results for its double-masked, placebo-controlled Phase II clinical trial of Squalamine eye drops in patients with wet age-related macular degeneration (wet AMD). The data demonstrated a positive benefit in visual function across multiple clinically relevant endpoints, including a mean change in visual acuity at the end of study visit for the interim analysis group of +10.4 letters with Squalamine eye drops plus Lucentis(R) PRN versus +6.3 letters in the placebo eye drops plus Lucentis PRN arm, a 65 percent additional relative benefit (p=0.18). OHR Pharmaceutical Inc (NASDAQ:OHRP) weekly performance is -21.48%. On last trading day company shares ended up $7.31. Analysts mean target price for the company is $21.00. OHR Pharmaceutical Inc (NASDAQ:OHRP) distance from 50-day simple moving average (SMA50) is -18.48%.
Leave a Reply